These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 15340733

  • 1. [Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis].
    Hanefeld M, Schaper F.
    Herz; 2004 Aug; 29(5):480-7. PubMed ID: 15340733
    [Abstract] [Full Text] [Related]

  • 2. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update.
    Ceriello A, Davidson J, Hanefeld M, Leiter L, Monnier L, Owens D, Tajima N, Tuomilehto J, International Prandial Glucose Regulation Study Group.
    Nutr Metab Cardiovasc Dis; 2006 Oct; 16(7):453-6. PubMed ID: 16934443
    [Abstract] [Full Text] [Related]

  • 3. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.
    Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M.
    Diabetes Care; 2008 Feb; 31 Suppl 2():S155-60. PubMed ID: 18227478
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S, Nakamura K, Takeuchi M.
    Med Hypotheses; 2005 Feb; 65(1):152-4. PubMed ID: 15893133
    [Abstract] [Full Text] [Related]

  • 5. Role of postprandial hyperglycemia in cardiovascular disease.
    Fava S.
    Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):859-72. PubMed ID: 18570623
    [Abstract] [Full Text] [Related]

  • 6. [Postprandial hyperglycemia and diabetic complications].
    Da Ros R, Assaloni R, Ceriello A.
    Recenti Prog Med; 2005 Sep; 96(9):436-44. PubMed ID: 16229326
    [Abstract] [Full Text] [Related]

  • 7. Clinical decision making: managing postprandial hyperglycemia.
    Hurel SJ, Mohan V.
    J Assoc Physicians India; 2006 Nov; 54():871-6. PubMed ID: 17249256
    [Abstract] [Full Text] [Related]

  • 8. Postprandial glucose regulation and diabetic complications.
    Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J.
    Arch Intern Med; 2004 Oct 25; 164(19):2090-5. PubMed ID: 15505121
    [Abstract] [Full Text] [Related]

  • 9. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes.
    Colette C, Monnier L.
    Horm Metab Res; 2007 Sep 25; 39(9):683-6. PubMed ID: 17846977
    [Abstract] [Full Text] [Related]

  • 10. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
    Delorme S, Chiasson JL.
    Curr Opin Pharmacol; 2005 Apr 25; 5(2):184-9. PubMed ID: 15780829
    [Abstract] [Full Text] [Related]

  • 11. Hyperglycaemic spikes as a risk factor of diabetic complications.
    Szybiñski Z.
    Przegl Lek; 2006 Apr 25; 63 Suppl 4():1-2. PubMed ID: 16969903
    [No Abstract] [Full Text] [Related]

  • 12. [Hyperglycemia and cardiovascular events].
    Schneider CA, Gallwitz B, Hanefeld M, Leschke M, Müller-Wieland D, Zeymer U, Erdmann E.
    Dtsch Med Wochenschr; 2004 Nov 19; 129(47):2553-7. PubMed ID: 15543474
    [Abstract] [Full Text] [Related]

  • 13. Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum.
    Karasik A.
    Ann Med; 2005 Nov 19; 37(4):250-8. PubMed ID: 16019723
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U.
    Int J Cardiol; 2006 Feb 08; 107(1):11-20. PubMed ID: 16337493
    [Abstract] [Full Text] [Related]

  • 15. Fasting and postchallenge hyperglycemia and risk of cardiovascular disease in Chinese: the Chin-Shan Community Cardiovascular Cohort study.
    Chien KL, Hsu HC, Su TC, Chen MF, Lee YT, Hu FB.
    Am Heart J; 2008 Nov 08; 156(5):996-1002. PubMed ID: 19061718
    [Abstract] [Full Text] [Related]

  • 16. [The best of epidemiology and cardiovascular prevention in 2006].
    Thomas D, Collet JP, Cottin Y, Cournot M, Ducimetière P, Ferrières J, Paillard F, Valensi P, Zeller M, Cambou JP.
    Arch Mal Coeur Vaiss; 2007 Jan 08; 100 Spec No 1():57-64. PubMed ID: 17405566
    [Abstract] [Full Text] [Related]

  • 17. Primary prevention of cardiovascular disease in people with dysglycemia.
    Bianchi C, Miccoli R, Penno G, Del Prato S.
    Diabetes Care; 2008 Feb 08; 31 Suppl 2():S208-14. PubMed ID: 18227487
    [Abstract] [Full Text] [Related]

  • 18. Defining the role of incretin mimetic therapy in the management of type 2 diabetes.
    Unger J, Nadeau DA.
    J Fam Pract; 2007 Dec 08; 56(12 Suppl New):S4-S10. PubMed ID: 18664341
    [Abstract] [Full Text] [Related]

  • 19. Postprandial hyperglycaemia in type 2 diabetes: pathophysiological aspects, teleological notions and flags for clinical practice.
    Boutati EI, Raptis SA.
    Diabetes Metab Res Rev; 2004 Dec 08; 20 Suppl 2():S13-23. PubMed ID: 15551342
    [Abstract] [Full Text] [Related]

  • 20. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor.
    O'Keefe JH, Bell DS.
    Am J Cardiol; 2007 Sep 01; 100(5):899-904. PubMed ID: 17719342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.